Summarily, our findings indicate that the combination of ZN-c3 and sotorasib is a more effective therapeutic strategy for both sotorasib-sensitive and (initially) sotorasib-resistant KRAS-G12C-mutated NSCLC with TP53 mutations. This evidence concerns the gene KRAS and non-small cell lung carcinoma.